IRRAS (OM:IRRAS) - Aktienkurs, Nachrichten und Analyse

IRRAS Aktienübersicht

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide.

Über das Unternehmen

IRRAS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 62.97%

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung (SEK182M)

Hat keine nennenswerten Einnahmen (SEK43M)

Die Aktionäre wurden im vergangenen Jahr verwässert

+ 1 mehr Risiko

IRRAS AB (publ) Wettbewerber

Nanexa

OM:NANEXA

kr120.0m

Medclair

NGM:MCLR

kr89.5m

Phase Holographic Imaging PHI

NGM:PHI

kr169.2m

Ortoma

OM:ORT B

kr293.7m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für IRRAS
Historische Aktienkurse
Aktueller Aktienkurs	kr0.16
52-Wochen-Hoch	kr0.63
52-Wochen-Tief	kr0.11
Beta	1.73
11 Monat Veränderung	-6.47%
3 Monate Veränderung	-10.39%
1 Jahr Veränderung	-64.36%
33 Jahre Veränderung	-97.58%
5 Jahre Veränderung	-99.58%
Veränderung seit IPO	-99.57%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	IRRAS	SE Medical Equipment	SE Markt
7D	-1.1%	-4.3%	-3.4%
1Y	-64.4%	-2.4%	14.3%

Rendite im Vergleich zur Industrie: IRRAS unter dem Niveau der Branche Swedish Medical Equipment, die im vergangenen Jahr eine Rendite von -8.3% erzielte.

Rendite vs. Markt: IRRAS hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 17 erzielte.

Preisvolatilität

Is IRRAS's price volatile compared to industry and market?
IRRAS volatility
IRRAS Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	7.0%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.7%
10% least volatile stocks in SE Market	3.5%

Stabiler Aktienkurs: IRRAS hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: IRRASDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2011	47	Will Martin	www.irras.com

IRRAS AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von IRRAS im Vergleich zum Marktanteil des Unternehmens?
IRRAS grundlegende Statistiken
Marktanteil	kr181.75m
Gewinn(TTM)	-kr196.40m
Umsatz(TTM)	kr43.10m

4.2x

Kurs-Umsatz-Verhältnis

-0.9x

Kurs-Gewinn-Verhältnis

Ist IRRAS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IRRAS Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr43.10m
Kosten der Einnahmen	kr44.03m
Bruttogewinn	-kr935.00k
Sonstige Ausgaben	kr195.47m
Umsatz	-kr196.40m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

Feb 21, 2024

Gewinn per Aktie (EPS)	-0.17
Bruttomarge	-2.17%
Nettogewinnspanne	-455.71%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich IRRAS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IRRAS Aktienübersicht

Belohnungen

Risikoanalyse

IRRAS AB (publ) Wettbewerber

OM:NANEXA

kr120.0m

NGM:MCLR

kr89.5m

NGM:PHI

kr169.2m

OM:ORT B

kr293.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

Erträge & Einnahmen